U.S. markets close in 9 minutes

Opthea Limited (OPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.59-0.36 (-4.53%)
As of 12:02PM EDT. Market open.
Full screen
Loading interactive chart...
  • Simply Wall St.

    We're Not Very Worried About Opthea's (ASX:OPT) Cash Burn Rate

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

  • GlobeNewswire

    Opthea To Present at September Investor Conferences

    MELBOURNE, Australia, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr Megan Baldwin, the Company’s Chief Executive Officer, will participate in the following investor conferences in September: Citi’s 16th Annual BioPharma Virtual ConferenceDate: Thursday, September 9, 2021 8:50 am ET (11:50 pm AEST)Panel: Eyes on the Prize – Next G

  • GlobeNewswire

    Opthea Reports Fiscal Year 2021 Financial Results and Corporate Highlights

    Treated First Patient in Phase 3 Pivotal Trials of OPT-302 in Wet Age-Related Macular Degeneration (AMD) OPT-302 Granted FDA Fast Track Designation for Wet AMD Received FDA Waiver for Pediatric Study Plan for OPT-302 in Wet AMD ShORe and COAST Phase 3 Clinical Trials Opened Recruitment to Patients in U.S. & Canada MELBOURNE, Australia, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prev